Protonix Settlement Leaves Question Of How Jury Would Assess At-Risk Launch Damages
This article was originally published in PharmAsia News
Teva and India’s Sun Pharma are to pay $2.15 billion for their at-risk launch in the U.S. of generic versions of Pfizer’s Protonix; Pfizer says figure represents lost profits and lost royalties from the three years the product faced premature generic competition.
You may also be interested in...
One day after declaring one Pulmicort patent invalid and another not infringed, a New Jersey federal judge granted AstraZeneca’s bid to temporarily block Actavis and other ANDA filers from launching and distributing their budesonide generics.
How risky are at-risk launches of generic products?
A jury finds that Pfizer's patent on the proton pump inhibitor is valid; analyst Timothy Anderson estimates that without a settlement Teva's damages could top $1 billion but thinks the actual impact will be smaller.